HIV and AIDS Trial, Recruiting NCT06013579 Sponsor: University of Alabama at Birmingham Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT06013579
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a confirmed HIV diagnosis
  • People who describe themselves as not very physically active — specifically, those who do less than 3 days per week of activity that makes them sweat, and who have not done regular strength/resistance exercise in the past 3 months
  • People who experience fatigue, based on a score of 2.0 or higher on the first two questions of a standard HIV-related fatigue questionnaire
  • People who have been on a current HIV treatment (antiretroviral therapy) regimen for at least 12 months
  • People whose HIV viral load has been below 200 copies/mL in the past 12 months, as shown in their medical records
  • People who are willing to attend a supervised exercise program 3 times per week for 4 months
  • People who have access to a cell phone or email to receive messages
  • People who weigh less than 450 pounds
  • People who have received medical clearance from the study's healthcare professional

Who may not be able to join:

  • People who weigh more than 450 pounds
  • People who have been taking sex hormone therapy for 3 months or less (those who have been on a stable dose for more than 3 months may still be considered)
  • People who have been taking other hormone replacement therapy for 3 months or less (those who have been on a stable dose for more than 3 months may still be considered)
  • People with anaemia — specifically, low haemoglobin levels (below 9 g/dL for women or below 10 g/dL for men)
  • People who have been diagnosed with a mitochondrial disease
  • People with active substance use issues, or other factors that the trial site's investigator believes could affect their safety or ability to complete study visits
  • People with high blood pressure that is not well controlled — specifically, a resting blood pressure reading above 150/90 mmHg (those who do not meet this at first screening may be re-evaluated after follow-up with their own doctor)
  • People with unstable heart disease, such as chest pain (angina) or abnormal heart rhythms detected at rest or during an exercise test, without a follow-up evaluation clearing them
  • People with more advanced heart failure (classified as New York Heart Association Class III or IV), significant narrowing of the aortic heart valve, or heart rhythm problems that are not well controlled
  • People with a lung condition that requires them to use supplemental oxygen either at rest or during physical activity
  • People who have received chemotherapy or radiation therapy for cancer within the past 24 weeks
  • People with poorly controlled diabetes, shown by a blood sugar marker (HbA1c) above 8.5 within the past 6 months, or who are currently using insulin
  • People who have had surgery, a significant injury, or a bone fracture within the past 24 weeks that the study clinician believes could affect their ability to exercise or complete baseline testing
  • People who have balance problems that could affect their ability to safely exercise or complete functional testing, either reported by the person themselves or noted in their medical records
  • People with significant joint or bone problems — such as severe osteoarthritis or rheumatoid arthritis — that greatly limit their ability to do moderate-level strength exercises
  • People whose overall health the study clinician considers to be unstable, or who the clinician believes cannot safely take part in the exercise program

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 205-996-0330

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 August 2023
Est. completion
1 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Cognition; Cognition; Cognition; Cognition

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov